logo
  

ITE Group Q1 Revenues Rise, LFL Revenues Down; Warns On Oil Producing Economies

ITE Group Plc (ITE.L), an exhibition organiser, said Thursday that its first-quarter trading was in line with management expectations. Revenue for the three month period was 34.8 million pounds, higher than last year's 25.4 million pounds. On a like-for-like basis, revenues for the quarter are, as expected, 13% behind the comparative period.

This year's first quarter result includes the acquisitions of Breakbulk, Africa Oil Week and the effect of ABEC becoming a subsidiary. These acquisitions, combined with the biennial pattern, have offset the challenging trading environment in Russia and Central Asia.

Looking ahead, the company said its results remain sensitive to the economic climate in the oil producing economies of Russia, Kazakhstan and Azerbaijan.

If the recent fall of the oil price is sustained, the economic situation in these countries is likely to deteriorate further. The company's like-for-like trading volumes are currently 10% less than this time last year, and like-for-like revenues are also 10% behind.

The Group will continue to drive underlying growth outside of the oil producing economies, building on the strategic action it has taken in recent years to successfully diversify the Group.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT